SEARCH:   Advanced

Blood, 15 March 2006, Vol. 107, No. 6, pp. 2330-2338. Prepublished online as a Blood First Edition Paper on December 1, 2005; DOI 10.1182/blood-2005-04-1655. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-04-1655v1 107/6/2330    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kertesz, N. Articles by Gill, P. S. Search for Related Content PubMed PubMed Citation Articles by Kertesz, N. Articles by Gill, P. S. Related Collections Hemostasis, Thrombosis, and Vascular Biology Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth Nathalie Kertesz, Valery Krasnoperov, Ramachandra Reddy, Lucy Leshanski, S. Ram Kumar, Sergey Zozulya, and Parkash S. Gill From Vasgene Therapeutics, Inc, and the Departments of Pathology, Surgery, and Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA. The receptor tyrosine kinase EphB4 and its ligand EphrinB2 play a crucial role in vascular development during embryogenesis. The soluble monomeric derivative of the extracellular domain of EphB4 (sEphB4) was designed as an antagonist of EphB4/EphrinB2 signaling. sEphB4 blocks activation of EphB4 and EphrinB2; suppresses endothelial cell migration, adhesion, and tube formation in vitro; and inhibits the angiogenic effects of various growth factors (VEGF and bFGF) in vivo. sEphB4 also inhibits tumor growth in murine tumor xenograft models. sEphB4 is thus a therapeutic candidate for vascular proliferative diseases and cancer. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Weinsheimer, H. Kim, L. Pawlikowska, Y. Chen, M. T. Lawton, S. Sidney, P.-Y. Kwok, C. E. McCulloch, and W. L. Young EPHB4 Gene Polymorphisms and Risk of Intracranial Hemorrhage in Patients With Brain Arteriovenous Malformations Circ Cardiovasc Genet, October 1, 2009; 2(5): 476 - 482. [Abstract] [Full Text] [PDF] H. Dopeso, S. Mateo-Lozano, R. Mazzolini, P. Rodrigues, L. Lagares-Tena, J. Ceron, J. Romero, M. Esteves, S. Landolfi, J. Hernandez-Losa, et al. The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis Cancer Res., September 15, 2009; 69(18): 7430 - 7438. [Abstract] [Full Text] [PDF] J. S. Scehnet, E. J. Ley, V. Krasnoperov, R. Liu, P. K. Manchanda, E. Sjoberg, A. P. Kostecke, S. Gupta, S. R. Kumar, and P. S. Gill The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade Blood, January 1, 2009; 113(1): 254 - 263. [Abstract] [Full Text] [PDF] D. Pfaff, M. Heroult, M. Riedel, Y. Reiss, R. Kirmse, T. Ludwig, T. Korff, M. Hecker, and H. G. Augustin Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes J. Cell Sci., November 15, 2008; 121(22): 3842 - 3850. [Abstract] [Full Text] [PDF] I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al. Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target Blood, August 1, 2008; 112(3): 750 - 759. [Abstract] [Full Text] [PDF] T. Korff, J. Braun, D. Pfaff, H. G. Augustin, and M. Hecker Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment Blood, July 1, 2008; 112(1): 73 - 81. [Abstract] [Full Text] [PDF] J. Masuda, R. Usui, and Y. Maru Fibronectin Type I Repeat Is a Nonactivating Ligand for EphA1 and Inhibits ATF3-dependent Angiogenesis J. Biol. Chem., May 9, 2008; 283(19): 13148 - 13155. [Abstract] [Full Text] [PDF] X. Huang, Y. Yamada, H. Kidoya, H. Naito, Y. Nagahama, L. Kong, S.-Y. Katoh, W.-l. Li, M. Ueno, and N. Takakura EphB4 Overexpression in B16 Melanoma Cells Affects Arterial-Venous Patterning in Tumor Angiogenesis Cancer Res., October 15, 2007; 67(20): 9800 - 9808. [Abstract] [Full Text] [PDF] J. S. Scehnet, W. Jiang, S. Ram Kumar, V. Krasnoperov, A. Trindade, R. Benedito, D. Djokovic, C. Borges, E. J. Ley, A. Duarte, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion Blood, June 1, 2007; 109(11): 4753 - 4760. [Abstract] [Full Text] [PDF] N. K. Noren and E. B. Pasquale Paradoxes of the EphB4 Receptor in Cancer Cancer Res., May 1, 2007; 67(9): 3994 - 3997. [Abstract] [Full Text] [PDF] I. Airoldi, E. Di Carlo, C. Cocco, G. Taverniti, T. D'Antuono, E. Ognio, M. Watanabe, D. Ribatti, and V. Pistoia From the Cover: Endogenous IL-12 triggers an antiangiogenic program in melanoma cells PNAS, March 6, 2007; 104(10): 3996 - 4001. [Abstract] [Full Text] [PDF] F. Diehl, L. Rossig, A. M. Zeiher, S. Dimmeler, and C. Urbich The histone methyltransferase MLL is an upstream regulator of endothelial-cell sprout formation Blood, February 15, 2007; 109(4): 1472 - 1478. [Abstract] [Full Text] [PDF] J. E. Chrencik, A. Brooun, M. L. Kraus, M. I. Recht, A. R. Kolatkar, G. W. Han, J. M. Seifert, H. Widmer, M. Auer, and P. Kuhn Structural and Biophysical Characterization of the EphB4{middle dot}EphrinB2 Protein-Protein Interaction and Receptor Specificity J. Biol. Chem., September 22, 2006; 281(38): 28185 - 28192. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020